On March 22, 2019, Medacta Group SA (Medacta), a high-growth pure-play orthopaedics company domiciled in Castel San Pietro, Switzerland, announced the launch of its Initial Public Offering (IPO) on SIX Swiss Exchange, the publication of the offering memorandum and the start of the bookbuilding process. The IPO comprises an offering by certain members of the Siccardi family (the Selling Shareholders) of up to 5,700,000 existing shares and an additional up to 855,000 existing shares to cover an over-allotment option granted by the Selling Shareholders to the underwriters. The expected market capitalization of Medacta following the IPO is CHF 1.8 bn to CHF 2.1 bn. The first trading day is anticipated to be April 4, 2019.
Credit Suisse AG and Morgan Stanley & Co. International plc are acting as Joint Global Coordinators and Joint Bookrunners, and UBS AG and J.P. Morgan Securities plc as Joint Bookrunners on the IPO.
Medacta is one of the world's fastest growing orthopaedics companies, with the majority of the revenues deriving from the high-volume hip and knee business lines, complemented by sales of shoulder and spine products. In 2018, Medacta generated revenues of EUR 273 m and an adjusted EBITDA of EUR 88 m. With a global workforce of approximately 970 employees, Medacta has a presence in 12 countries worldwide.
Homburger acts as counsel to the underwriters. The Homburger team is led by partner Frank Gerhard and includes associates Lorenzo Togni and Daniel Häusermann as well as junior associate Jasmin Künzle (all Corporate | M&A and Capital Markets). Partner Stefan Oesterhelt and associate Jan Seltmann (both Tax) provide tax advice.